



EP00/3982



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17 I(a) OR (b)

REC'D 15 JUN 2000

WIPO POT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

4

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

18 April 2000

Act 1977
16)



The
Patent
Office

06MAY99 E4449 0-1 001030
P01/7700 0.00 - 9910366.5

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your Reference	MA/PU3611		
2. Patent application number (The Patent office will fill in this part)	06 MAY 1999		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	<p>9910366.5</p> <p>GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 0NN, GB</p>		
Patents ADP number (if you know it)	473587003		
If the applicant is a corporate body, give the country/state of its corporation			
4 Title of the invention	1,5-BENZODIAZEPINE DERIVATIVES		
5 Name of your agent (if you know one)	MICHAEL ATKINSON (SEE CONTINUATION SHEET)		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	GLAXO WELLCOME PLC GLAXO WELLCOME HOUSE, BERKELEY AVENUE GREENFORD, MIDDLESEX UB6 0NN, GB		
Patents ADP number (if you know it)			
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES		

See note (ii)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	20
Claim(s)	3
Abstract	1
Drawing(s)	-

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patent Form 9/77)

Request for substantive examination (Patent Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature Michael Atkinson

5 May, 1999

AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

Kim Allen
0181-966 5721

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office

Additional Agents
(See Page 1 No. 5)

NAME(S)

Alan HESKETH
William Michael DADSON
Michael ATKINSON
Karen CRAWLEY
Peter I. DOLTON
Hugh B. DAWSON
Wendy Anne FILLER
Ruth Elizabeth HACKETT
Catriona MacLeod HAMMER
Audrey HAMMETT
Graham M.H. LANE
Stephanie Anne LEAROYD
Helen Kaye QUILLIN
Michael A REED
Marion REES
Michael John STOTT
Andrew J. TEUTEN
Rachel M. THORNLEY
Janis Florence VOLCKMAN

ADDRESS

Glaxo Wellcome plc
Glaxo Wellcome House
Berkeley Avenue
Greenford
Middlesex
UB6 ONN
Great Britain

1,5-Benzodiazepine Derivatives

This invention relates to novel 1,5-benzodiazepine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors.

Cholecystokinin (CCK) is a peptide found in the gastrointestinal tract and the central nervous system. see A.J. Prange *et al.*, *Ann. Reports Med. Chem.* 17, 31, 33 (1982), J. A. Williams, *Biomed Res.* 3, 107 (1982) and V. Mutt, *Gastrointestinal Hormones*, G.B.J. Green, Ed., Raven Press, N.Y., 169. CCK has been implicated *inter alia* as a physiological satiety hormone involved in appetite regulation, see Della-Ferra *et al.*, *Science*, 206, 471 (1979), Saito *et al.*, *Nature*, 289, 599, (1981), G.P. Smith, *Eating and Its Disorders*, A.J. Stunkard and E. Stellar, Eds, Raven Press, New York, 67 (1984), as a regulator of gallbladder contraction and pancreatic enzyme secretion, an inhibitor of gastric emptying, and as a neurotransmitter, see A.J. Prange, *supra*, J.A. Williams, *Biomed Res.*, 3, 107 (1982), J.E. Morley, *Life Sci.* 30, 479, (1982). Gastrin is a peptide involved in gastric acid and pepsin secretion in the stomach, see L. Sandvik, *et al.*, *American J. Physiology*, 260, G925 (1991), C.W. Lin, *et al.*, *American J. Physiology*, 262, G1113, (1992). CCK and gastrin share structural homology in their C-terminal tetrapeptide: Trp-Met-Asp-Phe.


Two subtypes of CCK receptors have been identified, designated as CCK-A and CCK-B, and both have been found in the periphery and central nervous systems. It has recently been reported that CCK-B receptors are similar to the gastrin receptor, see Pisegna, J.R., de Weerth, A, Huppi, K, Wank, S.A., *Biochem. Biophys. Res. Commun.* 189, 296-303 (1992). CCK-A receptors are located predominantly in peripheral tissues including the pancreas, gallbladder, ileum, pyloric sphincter and vagal afferent nerve fibers; CCK-A receptors are found to a lesser extent in the brain, see T.H. Moran, *et al.*, *Brain Res.*, 362, 175-179

(1986), D.R. Hill, *et al.*, *Brain Res*, 4545, 101, (1988), D.R. Hill, *et al.*, *Neurosci Lett.*, 89, 133, (1988), R.W. Barret, *et al.*, *Mol. Pharmacol.*, 36, 285, (1989), D.R. Hill, *et al.*, *J. Neurosci*, 10, 1070 (1990), V. Dauge *et al.*, *Pharmacol Biochem Behav.*, 33, 637, (1989), while CCK-B receptors are found predominantly in the
5 brain, see V.J. Lotti and R.S.L Chang, *Proc. Natl. Acad. Sci. U.S.A.*, 83, 4923 (1986), J.N. Crawley, *Trends Pharm. Sci.*, 88, 232, (1991).

CCK agonist activity has been linked to inhibition of food intake in animals and thus weight loss, see Della-Fera, *et al, supra*, K.E. Asin, *et al, Intl. Conference on*
10 *Obesity*, abstract pp.40 (1990). It has been suggested that CCK acts in the periphery through vagal fibers and not directly on the brain to produce satiety, see Smith, G.P. and Cushin, B.J., *Neuroscience Abstr.*, 4, 180 (1978), Smith, G.P., Jerome, C., Cushin, B.J., Eterno, R., and Simansky, K.J., *Science*, 212, 687-689, (1981).

15 U.S. Patent No. 5,646,140 (Sugg, *et al.*) discloses certain 3-amino 1,5-benzodiazepine compounds which exhibit agonist activity for the CCK-A receptor thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals. See in particular, the compound of Example 7. Certain of
20 these compounds also exhibit antagonist activity at CCK-B receptors.

Briefly, in one aspect, the present invention provides an enantiomerically enriched compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof.



The compound of Formula (I) is 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido}

benzoic acid. This compound has a chiral carbon on the benzodiazepine ring.

Applicants have found that the enantiomer which rotates light in the positive
5 direction, under the conditions described below, is preferred. This enantiomer is hereinafter referred to as the (+) enantiomer. Applicants have found that this isomer has improved properties over the racemic mixture and is therefore more suitable than the racemic mixture for the treatment of obesity and other CCK-A mediated diseases or conditions. As used herein, "enantiomerically enriched"
10 means that there is more of the (+) enantiomer than the (-) enantiomer as opposed to the racemic mixture which has equal amounts of each isomer. As used herein "the compound of this invention" or "the enantiomerically enriched compound of this invention", and expressions containing these or similar phrases, include pharmaceutically acceptable salts and solvates thereof. The "(+)
15 enantiomer" refers to the optical rotation of the enantiomer and not to salts and solvates thereof. Preferred salts and solvates will be salts and solvates of the (+) enantiomer of the compound of Formula (I) regardless of the optical rotation of the salt or solvate.

20 Preferably, the (+) enantiomer is at least %90 of the total amount of the enantiomerically enriched compound. More preferably, the (+) enantiomer is at least %96 of the total amount of the compound. Most preferably, the (+) enantiomer is at least %99 of the total amount of the compound.

25 In another aspect, the present invention discloses a pharmaceutical composition comprising the enantiomerically enriched compound of this invention.

According to another aspect, the present invention provides the use of the enantiomerically enriched compound of this invention or a pharmaceutically
30 acceptable salt or solvate thereof for the manufacture of a medicament for the


treatment of conditions where modification of the effects of CCK and/or gastrin is of therapeutic benefit.

5 The (+) enantiomer of the present invention exhibits CCK-A agonist activity and can be considered a full cholecystokinin agonist in that it binds to CCK-A receptors and fully stimulates gallbladder contraction and reduces feeding in animal paradigms. Therefore, in a further aspect of the present invention, there is provided herein a method for the treatment, in a mammal, including man, of a CCK-A mediated disease or condition comprising administering to the patient a
10 therapeutically effective amount of a composition of this invention. For example, the composition of this invention should be useful for the treatment of obesity as well as related pathologies, such as hypertension, gallbladder stasis, and diabetes, indirectly through weight loss and directly through CCK-A mediated delayed gastric emptying. Moreover, the (+) enantiomer disclosed herein
15 provides for new approaches for inducing satiety, providing for appetite regulation and modifying food intake in mammals, especially humans, to regulate appetite, treat obesity and maintain weight loss.


20 The (+) enantiomer of this invention can be made by first making the racemic mixture as described in Example 7 in U.S. Patent No. 5,646,140 and then separating the enantiomers by chiral chromatography.

Alternatively the (+) enantiomer may be prepared by reaction of the appropriate enantiomer of the amine of formula (II);

25




- with an isocyanate of formula (III; wherein R is a carboxyl protecting group e.g. t-butyl), an imidazolidine of formula (IV; wherein R is a carboxyl protecting group e.g. t-butyl) or an optionally substituted phenyl carbonate of formula (V; wherein R is a carboxyl protecting group e.g. t-butyl and R₁ is hydrogen or a conventional phenyl substituent e.g. NO₂) followed by removal of the carboxyl protecting group R.



- 10 The reaction conveniently takes place in the presence of a suitable solvent such as an ether (e.g. tetrahydrofuran) or a halohydrocarbon (e.g. dichloromethane) or nitrile (e.g. acetonitrile) at a temperature in the range of 0-80°C.
- Conveniently the required enantiomer of the amine (II) may be used in the form of a salt thereof e.g. R-camphorsulphonic acid salt and in this embodiment the
- 15 the reaction is carried out in the presence of a base e.g. of a tertiary amine such as triethylamine.

The hydrolysis of the carboxyl protecting group may be carried out using conventional procedures. Thus for example when R is a t-butyl group this may be removed by hydrolysis with hydrochloric acid or trifluoroacetic acid using established procedures. (Protecting groups in Organic Synthesis T. Greene, Ed, Wiley Interscience, New York, p168, 1981).

The required enantiomer of the amine of Formula (II);



10 can be prepared by resolution of the corresponding racemic amine via chiral HPLC chromatography or through crystallization-induced asymmetric resolution via the R-camphorsulfonic acid salt.

The racemic amine II can be prepared by the method described in Intermediate
15 11 of US Patent No. 5,646,140.

Isocyanates of Formula (III) may be purchased or prepared by the reaction of the corresponding amine (VI) with phosgene or triphosgene in a suitable solvent such as methylene chloride. Imidazolides of Formula (IV) can be prepared by treatment of the corresponding amine (VI) with carbonyl diimidazole in a suitable solvent (dichloromethane, ether, tetrahydrofuran) at a temperature ranging from 0 - 80° C (conveniently at room temperature). The optionally substituted phenyl carbamates of Formula (V) can be prepared by the reaction of the corresponding

amine (VI) with the optionally substituted phenyl chloroformate in the presence of a base (pyridine, triethylamine) in a suitable solvent (dichloromethane) and at a temperature of 0 - 50° C. The amines of formula (VI) are either known compounds and can be prepared by procedures analogous to those used to
5 prepare the known compounds.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms. Moreover, it will be appreciated that the amount of the preferred
10 enantiomer of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of 0.02 - 5000 mg per day, e.g., 1-1500 mg per day. The desired dose
15 may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

While it is possible that the preferred enantiomer of the present invention may be
20 therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical composition. Accordingly, the present invention further provides for a pharmaceutical composition comprising the enantiomerically enriched compound of this invention together with one or more pharmaceutically acceptable carriers therefore and, optionally, other therapeutic
25 and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Formulations of the present invention include those especially formulated for oral,
30 buccal, parenteral, implant, or rectal administration, however, oral administration is preferred. For buccal administration, the composition may take the form of

tablets or lozenges formulated in conventional manner. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulphate. The tablets may be coated according to methods well-known in the art.

10

Alternatively, the preferred enantiomer of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example. Moreover, formulations containing these the preferred enantiomer may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid. Such preparations may also be formulated as suppositories, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

25

Additionally, compositions the present invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder

30

form for constitution with a suitable vehicle (e.g., sterile, pyrogen-free water) before use.

5 The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Accordingly, the preferred enantiomer of the invention may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins or as sparingly soluble derivatives as a
10 sparingly soluble salt, for example.

The compositions according to the invention may contain between 0.1 - 99% of the active ingredient, conveniently from 30 - 95% for tablets and capsules, and 3 - 50% for liquid preparations.

15

The following examples which are non-limiting illustrate the invention.

Intermediate 1

20 (+)-2-(3-Amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepin-1-yl)-N-isopropyl-N-phenylacetamide camphorsulfonic acid salt
(+/-)-2-(3-Amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepin-1-yl)-N-isopropyl-N-phenylacetamide (10g, 1equiv) and R-camphorsulfonic acid (4.98g, 0.95equiv) were stirred in tetrahydrofuran (35ml) and toluene (65ml) to give a solution. The solution was heated to 70°C with formation of a suspension.
25 Water (0.4ml) was added followed by a solution of 2-pyridinecarboxaldehyde (0.24g, 0.1equiv) in toluene (5ml). The mixture was heated at 70°C for 3h and then cooled to 25°C over 5h and stirred at 25°C for 16h. The suspension was chilled to 0-5°C for 1.5h. The solid was collected by filtration washing with toluene/tetrahydrofuran (2:1) (10ml). Drying in vacuo at 50°C yielded the title
30 compound as a white solid (12.6g, 83%). Chromatographic analysis: Eluent:

- 30% Isopropyl Alcohol, 70% Heptane + 0.05% Diethylamine; Column: 25cm x 4.6mm i.d., Chiralpak AD; Flow rate: 1mL/minute; Temperature: 40 degrees C; Detection: UV 230nm; Injection volume: 10 μ L; Sample solution: 0.1mg/mL; sample in 30% Isopropyl alcohol, 70% Heptane. Sample solutions were injected immediately after preparation. Retention times: (+) enantiomer, 8.2 minutes. The unwanted (-) Enantiomer (12.7minutes) was below limits of detection.

Intermediate 2

3-Nitrobenzoic acid t-butyl ester

- Potassium t-butoxide (3.82 g, 32.30 mmol) was added to a solution of 3 nitrobenzoyl chloride (5.00 g, 26.94 mmol) in anhydrous tetrahydrofuran (70 ml) and stirred under nitrogen for 2 hrs. The reaction mixture was concentrated *in vacuo* and partitioned between dichloromethane and water. After separating the phases, the aqueous layer is back-extracted with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered and then concentrated *in vacuo*. The crude product was purified on flash grade silica gel using 0-5% gradient of ethyl acetate in n-hexane. Fractions containing the product were combined, concentrated *in vacuo*, and then dried under high vacuum to provide the title compound as an oil (3.82 g, 17.1 mmol). ^1H NMR (300 MHz, CDCl_3) δ = 1.63 (s, 9H); 7.62 (t, J=7.9 Hz, 1H); 8.29-8.41 (m, 2H); 8.78-8.80 (m, 1H). MS (CI): $[\text{M}+\text{H}]^+ = 224$.

Intermediate 3

3-Amino-benzoic acid t-butyl ester

- A solution of 3-nitro-benzoic acid t-butyl ester (3.77 g, 16.9 mmol), in absolute ethanol (50 ml) was combined with palladium on carbon (10 wt%, 0.30 g) and stirred under atmospheric hydrogen for approximately 3 hrs. The reaction mixture was filtered through a pad of diatomaceous earth and then concentrated *in vacuo* to an oil which crystallized when dried under high vacuum providing the title compound as a tan solid (3.28 g, 16.9 mmol). ^1H NMR (300 MHz, CDCl_3) δ =

1.58 (s, 9H); 6.79-6.87 (m, 1H), 7.19 (t, J=8.5 Hz, 1H); 7.24-7.34 (m, 1H); 7.38 (d, J=8.0 Hz, 1H). MS (CI): $[M+H]^+ = 194$.

Intermediate 4

5 3-Isocyano-benzoic acid t-butyl ester

Triphosgene (13.428 g, 45.25 mmol) was added to a solution of 3-amino-benzoic acid t-butyl ester (26.50 g, 137.13 mmol) and triethylamine (38.23 mL, 274.28 mmol) in anhydrous tetrahydrofuran (600 ml) at 0-5 °C. The reaction mixture was stirred at 0-5 °C for 2h, then concentrated *in vacuo* to a white solid. The crude product was slurried in hexane (500 ml), filtered, and the filtrate was concentrated *in vacuo* to afford the title compound as an oil (21.54 g, 71.6%). The crude isocyanate was used without further purification. ¹H NMR (300 MHz, CDCl₃) δ= 1.59 (s, 9H); 7.23 (bd, J=7.8 Hz, 1H); 7.36 (t, J=7.8 Hz, 1H); 7.69 (bs, 1H); 7.81 (d, J=7.8 Hz, 1H).

15

Intermediate 5

(+)-3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid t-butyl ester

Intermediate (I; 66.30 g, 98.25 mmol) was slowly added to a solution of 3-Isocyano-benzoic acid t-butyl ester (21.54 g, 98.25 mmol) in anhydrous tetrahydrofuran (750 ml). Triethylamine (13.70 ml, 98.29 mmol) was added dropwise to the reaction mixture. The resulting reaction mixture was stirred at ambient temperature overnight. The reaction mixture was poured into water (3000 ml) to afford a white solid. The solid was collected by filtration washing with water (3 X 500 ml). Drying by vacuum filtration yielded the title compound as a white solid (65.01 g, 100%). The crude title compound was used without further purification. Chromatographic characterization: Eluent: 30%Isopropyl Alcohol, 70% Heptane + 0.05% Diethylamine. Column: 25cm x4.6mm i.d., Chiralpak AD; Flow rate: 1mL/minute; Temperature: 40 degrees C; Detection: UV 230nm; Injection volume: 10 µL; Sample solution: 0.1mg/mL sample in 30%

Isopropyl alcohol, 70% Heptane. Sample solutions were injected immediately after preparation. Retention times: (+) enantiomer : 15.6 minutes. The unwanted (-) enantiomer: (13.3 minutes) was below the limits of detection.

5 **Example 1**

Chromatographic Resolution of Enantiomers

(+) and (-)-3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid.

Racemic 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid was prepared as described for example 7 in U.S. Patent No. 5,646,140 and resolved by chiral HPLC under the following conditions: a 250 x 4.0 μ m (id) column, 5 μ m Diacel Chiracel OD-R; the eluent was 80:20:0.1:1, 80 parts acetonitrile, 20 parts water, 0.1 part triethylamine, and 1 part acetic acid; the UV detection wavelength was 230nm; the temperature was ambient; the flow rate was 1ml/min; and the injection volume was 20 μ l. Under these conditions the (+) enantiomer had a retention time of 6.50 minutes and the (-) isomer had a retention time of 3.89 minutes.

20 **Example 2**

(+)-3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid

(+)-3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid t-butyl ester (65.01 g, 98.24 mmol) was stirred in 4N hydrochloric acid in dioxane (280 ml) at ambient temperature for 6h. The reaction mixture was concentrated *in vacuo* and the resulting solid/oil was triturated in water to afford a white solid. The white solid was collected by filtration and washed with water (2 X 500 ml). The crude product was dissolved in hot acetone (250 ml) and water (275 ml) was added until the solution became cloudy. Additional acetone (40 ml) was added and the solution was heated until a clear solution was obtained. The solution was set

aside and allowed to cool. The resulting white solid was collected by filtration washed with water (3 X 100 ml) and dried under house vacuum (20-25 in Hg) at 40-50 °C to provide the title compound as a white solid (40.496 g, 68%). Analyzed for purity by chiral chromatography (see chromatographic resolution protocol). Optical rotation (0.712g in 100mL acetone) $[\alpha]_D = +84.3$. ^1H NMR (300 MHz, DMSO) δ = 0.95 (d, J=7.5 Hz, 3H); 0.97 (d, J=7.2 Hz, 3H); 4.18 (d, J=16.7 Hz, 1H); 4.48 (d, J=16.7 Hz, 1H); 4.78 (m, 1H); 5.02 (d, J=7.8 Hz, 1H); 6.91 (d, J=7.8 Hz, 1H); 6.95 (bd, J=8.1 Hz, 1H); 7.22-7.57 (m, 19H); 8.00 (s, 1H); 9.34 (s, 1H); 12.78 (s, 1H). MS (ES): $[M+1] = 606.1$; $[M+\text{Na}] = 628.1$; $[M-1] = 604.1$.

10

BIOLOGICAL ASSAYS

The (+) and (-)-enantiomers and the racemic mixture were characterized in the following assays. The results of these assays are summarized in the table below.

- 15 **Guinea Pig Gallbladder Tissue Preparation.** Gallbladders were removed from male Hartley guinea pigs sacrificed with CO_2 atmosphere. The isolated gallbladders were cleaned of adherent connective tissue and cut into two rings from each animal (2-4 mm in length). The rings were suspended in organ chambers containing a physiological salt solution (118.4 mM NaCl, 4.7 mM KCl, 20 1.2 mM MgSO_4 , 2.5 mM CaCl_2 , 1.2 mM KH_2PO_3 , 25 mM NaHCO_3 , 11.1 mM dextrose). The bathing solution was maintained at 37°C and aerated with 95% O_2 /5% CO_2 to maintain pH = 7.4. Tissues were connected via gold chains and stainless steel mounting wires to isometric force displacement transducers (Grass, Model FT03 D). Responses were then recorded on a polygraph (Grass, 25 Model 7E). One tissue from each animal served as a time/solvent control and did not receive test compound. Rings were gradually stretched (over a 120-min. period) to a basal resting tension of 1 gm which was maintained throughout the experiment. During the basal tension adjustment period, the rings were exposed to acetylcholine (10^{-6} M) four times to verify tissue contractility. The tissues were 30 then exposed to a submaximal dose of sulfated CCK-8 (Sigma, 3×10^{-9} M).

After obtaining a stable response, the tissues were washed out 3 times rapidly and every 5 to 10 minutes for 1 hour to reestablish a stable baseline.

5 **Agonist EC₅₀'s.** Compounds were dissolved in dimethylsulfoxide (DMSO) then diluted with water and assayed via a cumulative concentration-response curve to test compound (10^{-11} to 3×10^{-5} M) followed by a concentration-response curve to sulfated CCK-8 (10^{-10} to 10^{-6} M) in the presence of the highest concentration of the test compound. As a final test, acetylcholine (1 mM) was added to induce maximal contraction. A minimum of three determinations of activity were made
10 for each test compound.

15 **Antagonist pA₂'s.** Gallbladder tissues from at least three different animals were incubated for 60 min with a given concentration (3 - 5 concentrations per analog) of the antagonist followed by a cumulative concentration response curve with CCK-8 or compound 1. One paired tissue from each animal did not receive the antagonist and served as the time/solvent control used to calculate the concentration ratio for the rightward shift in the CCK-8 concentration response. pA₂'s were determined by Schild analysis for a given number of observations²³. Upper and lower 95% confidence limits and slopes of the Schild plot are given for
20 each pA₂.

25 **Establishment of stable CCK receptor bearing cell lines.** The cDNA clones for the human CCK-A¹⁸ or CCK-B¹⁹ receptors were ligated into pcDNA1-Neo vector from Invitrogen Corp (San Diego, CA) for direct transfection. DNA was prepared by the alkaline lysis method and transfected into CHO-K1 cells (ATCC, Rockville, MD) using the Lipofectin reagent²⁴ (Gibco BRL, Gaithersburg, MD). Stable transfectants were initially selected by the use of Geneticin (Gibco BRL) and receptor bearing resistant cells were enriched by fluorescence-activated cell sorting based on binding of Fluorescein-Gly-[(Nle²⁸,31]-CCK-8. Clonal lines
30 were subsequently established by the limiting dilution method.

Cell Membrane Preparation. CHO-K1 cells stably transfected with human CCK-A or CCK-B receptor cDNA were grown at 37°C under a humidified atmosphere (95% O₂/5% CO₂) in Ham's F12 medium supplemented with 5% heat inactivated fetal bovine serum. The cells were passaged twice weekly and grown to a density of 2-4 million cells/mL. The cells were collected by centrifugation (600 X g, 15 min, 4°C) and resuspended in buffer (20 mL, pH 7.4) containing TrisHCl (25 mM), EDTA (5 mM), EGTA (5 mM), phenyl sulfonyl fluoride (0.1 mM) and soybean trypsin inhibitor (100 µg/mL). Cells were disrupted with a motorized glass teflon homogenizer (25 strokes) and the homogenate was centrifuged at low speed (600 X g, 10 min, 4°C). The supernatant was collected and centrifuged at high speed (500,000 X g, 15 min 4°C) to pellet the particulate fraction. The low speed pellet was processed three additional times. High-speed particulate fractions were combined and resuspended in buffer (1-5 mg protein/mL) and frozen at -80°C. Protein concentration was determined according to manufacturer's directions using BioRad reagent and bovine serum albumin as standard.

Receptor Binding Assays. ¹²⁵I-Bolton Hunter CCK-8 (Amersham, 2000 Ci/mmol) was dissolved in binding buffer (pH 7.4, 100,000 cpm/25 µL) containing HEPES (20 mM), NaCl (118 mM), KCl (5 mM), MgCl₂ (5 mM) and EGTA (1 mM). Nonspecific binding was determined with MK-329²⁰ (10 µM, CCK-A) or L-365,260²¹ (10 µM, CCK-B). Test compounds were dissolved in DMSO at a stock concentration of 100 times the final assay concentration and diluted to appropriate concentrations with binding buffer. Binding assays were performed in triplicate using 96-well plates to which the following were added sequentially: test compound (25 µL), ¹²⁵I-Bolton Hunter CCK-8 (25 µL), buffer (pH 7.4, 150 µL) and receptor preparation (50 µL). The final concentration of DMSO was 1% in all assay wells. After 3 hours at 30°C, the incubation was terminated by rapid

filtration of the mixture onto glass filters (Whatman GF/B) with subsequent washing to remove unbound ligand. Bound radioactivity was quantified by gamma counting.

- 5 **Intracellular Calcium Measurements:** CHO-K1 cells stably transfected with hCCK-A or hCCK-B receptors were grown on glass coverslips to 75-90% confluency. The cells were loaded for 50 minutes in serum-free culture medium containing 5 mM FURA2-AM and 2.5 mM probenecid. A JASCO CAF-102 calcium analyzer was used to measure changes in intracellular calcium
- 10 concentration by standard ratiometric techniques using excitation wavelengths of 340 nm and 380 nm. Cells were perfused with increasing concentrations of CCK-8 ($n = 2$) or compounds ($n = 2$) until a plateau in the 340/380 ratio was achieved. A washout/recovery period of at least 10 minutes was allowed between successive stimulations. The maximal response was normalized to the maximal
- 15 response induced by CCK-8. EC_{50} 's were calculated at the concentration required to induce half-maximal response. In addition to the agonist concentration-response curves, the CHO-K1 cells expressing the human CCK-B receptor were perfused for 1 hour with three concentrations of compounds (10^{-8} , 10^{-7} , 10^{-6} M, $n = 2$), then a concentration response curves were acquired for
- 20 CCK-8 (10^{-12} to 10^{-6} M).

- Anorexia Assays:** Male Long-Evans rats (225-300 g) were conditioned for two weeks to consume a palatable liquid diet (Bio-Serve F1657, Frenchtown, NJ) after a 2 hr fast. On pretreatment day, rats were fasted (100 min) and injected IP
- 25 with drug vehicle (propylene glycol, PG, 1 mL/kg) and an oral preload of saline (0.9% NaCl, 8 mL/kg). Liquid diet access was provided 20 min later and consumption was measured at 30, 90 and 180 min. To qualify for the drug treatment study, rats had to consume at least 8 mL of liquid diet within the first 30 minutes on the pretreatment day. The next day, following the 100 min
- 30 deprivation, rats (8 - 10 animals per dose) were treated IP or PO with vehicle (PG, 1 mL/kg) or various doses (0.01 to 10 μ mol/kg) of test compound dissolved

in PG (1 mL/kg), immediately followed by the saline oral preload. Food access was again provided 20 min later and food intake was measured at 30, 90 and 180 min. All food intake data were normalized for each rat to the respective values from the pretreatment day. Potency was determined at 30 min and efficacy at the 30 min, 1 μ mol/kg dose.

Mouse gallbladder emptying assay: Makovec, F.; Bani, M.; Cereda, R.; Chiste, R.; Pacini, M. A.; Revel, L.; Rovati, L. C. Antispasmodic Activity on the Gallbladder of the Mouse of CR1409 (Lorglumide), a Potent Antagonist of Peripheral Cholecystokinin. *Pharmacol. Res. Commun.* **1987**, *19*, 41-51.

Pharmacological Comparison of Enantiomers & Racemate

Assay	(+) Enantiomer	(-) Enantiomer	Racemate
<i>in vitro</i>			
GPGB EC ₅₀ (nM)	9.3	63	40
hCCK-A IC ₅₀ (nM)	148	191	123
hCCK-A EC ₅₀ (nM)	150	298	252
hCCK-B K _i (nM)	3.2	22.3	10
hCCK-B EC ₅₀ (nM)	Antagonist	Antagonist	Antagonist
Selectivity Ratio ¹	46	8.6	12.3
pApp (x 10 ⁻⁷ cm/sec)	1.6		0.7
<i>in vivo</i>			
Rat Anorexia			
ED ₅₀ IP (μmol/kg)	0.034	0.48	0.06
ED ₅₀ PO (μmol/kg)	1.1		2.0
Mouse Gallbladder Emptying Assay			
ED ₅₀ IP (μmol/kg).	0.002	0.012	0.007
ED ₅₀ PO (μmol/kg)	0.007	Inactive ²	0.055

1. Selectivity ratio = IC₅₀ (hCCK-A)/IC₅₀ (hCCK-B)

5

2. Inactive up to 10 μmol/kg

Three unexpected biological activities distinguish the (+) enantiomer from the (-) enantiomer and the racemate. Two of these activities relate to enhanced CCK-A

efficacy, which should improve the beneficial activity of this enantiomer. The third relates to the CCK-B antagonist activity of the (+) enantiomer which should prove beneficial through decreased toxicity.

- 5 The (+) enantiomer was four-fold more potent than the racemate in the in vitro isolated guinea pig gallbladder test ("GPGB"). The (+) enantiomer was eight-fold more potent than the racemate in the mouse gallbladder emptying assay (oral dosing). This increased potency is expected to be beneficial in the treatment of gallbladder stasis and in the treatment of obesity, since gallbladder stasis is a
10 critical problem with rapid weight loss.

- Anorectic agents are intended for chronic use and thus it is essential that they possess minimal risk for toxicity. The primary toxicity associated with the use of cholecystokinin is concomitant CCK-B receptor agonist activity. Activation of the
15 CCK-B receptor is primarily associated with increased anxiety and increased gastric acid secretion. The utility of CCK-B antagonists have been explored for both the development of anxiolytic agents and anti-ulcer agents. See, for example, Lowe, J, "Cholecystokinin-B Receptor Antagonists" in Exp. Opin. Ther. Patents, 5(3), pp 231-237 (1995).


- 20 The predominant CCK receptor subtype in the rodent pancreas is the CCK-A subtype and activation of this subtype induces pancreatic hyperstimulation and hypertrophy in rodents. Both of these activities are considered to be undesirable. Recently, the tissue distribution of CCK receptors in human tissues has been
25 reported. Surprisingly, the predominate receptor subtype in human pancreas is the CCK-B receptor subtype. See, for example, Wank, S. A., "Cholecystokinin Receptors" in American Journal of Physiology - Gastrointestinal & Liver Physiology, 32(5):, pp G628-G646, (1995). Thus, in humans, activation of the CCK-B receptor (CCK-B agonist activity) could induce increased anxiety and
30 gastric acid secretion, as well as pancreatic hyperstimulation and hypertrophy with long term use.

In order to decrease the risk of undesirable in vivo CCK-B agonist activity, the preferred compound should have affinity for the CCK-B receptor and have measurable CCK-B antagonist activity in in vitro assays. Both enantiomers and the racemate are CCK-B antagonists. Although all three compositions have similar human CCK-A receptor affinities (IC₅₀) and efficacies (EC₅₀), the (+) enantiomer has the highest CCK-B receptor affinity (IC₅₀) and selectivity (46-fold). Thus, the (+) enantiomer is preferred both in terms of CCK-A potency and efficacy, as well as in terms of the minimal potential for CCK-B induced toxic side effects.

What is Claimed is:

1. Enantiomerically enriched 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid, or a pharmaceutically acceptable salt or solvate thereof.
5
2. The enantiomerically enriched compound of Claim 1 wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 90% of said compound.
10
3. The enantiomerically enriched compound of Claim 1 wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 99% of said compound.
- 15 4. A pharmaceutical composition comprising the enantiomerically enriched compound of Claim 1.
5. A pharmaceutical composition comprising the enantiomerically enriched compound of Claim 2.
- 20 6. A pharmaceutical composition comprising the enantiomerically enriched compound of Claim 3.
7. A method for treating a CCK-A mediated disease or condition comprising
25 administration of the pharmaceutical composition of Claim 4.
8. A method for treating a CCK-A mediated disease or condition comprising administration of the pharmaceutical composition of Claim 5.
- 30 9. A method for treating a CCK-A mediated disease or condition comprising administration of the pharmaceutical composition of Claim 6.




10. The method of Claim 7 wherein said disease or condition is obesity, gallbladder stasis, or diabetes.
- 5 11. The method of Claim 8 wherein said disease or condition is obesity, gallbladder stasis, or diabetes.
12. The method of Claim 9 wherein said disease or condition is obesity, gallbladder stasis, or diabetes.
- 10 13. The method of Claim 7 wherein said disease or condition is obesity.
14. The method of Claim 8 wherein said disease or condition is obesity.
- 15 15. The method of Claim 9 wherein said disease or condition is obesity.
16. A process for the preparation of a compound as claimed in claim 1 which comprises:
 - 20 (a) resolution of racemic 3-[3-[1-(isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]benzoic acid by chiral hplc;
 - (b) reaction of the appropriate enantiomer of the amine of formula (II).



(II)

With the isocyanate of formula (III), imidazolidine of formula (IV) or optionally substituted phenyl carbamate of formula (V) followed by removal of the carboxy protecting group R.

5



17. The use of a compound as claimed in any of claims 1 to 3 in the manufacture of a medicament for use in the treatment of CCK-A mediated diseases.

10

ABSTRACT OF THE DISCLOSURE

An enantiomerically enriched compound of Formula (I) is disclosed. This compound is a CCK-A agonist and is therefore useful for the treatment of CCK-A
5 mediated diseases or conditions, such as obesity.

